Možnosti rehabilitace u pacientů po prodělaném onemocnění covid-19

Mgr. Monika Mikulášková, Mgr. Barbora Imrichová, doc. Mgr. Kateřina Neumannová, Ph.D.

Dermatol. praxi. 2021;15(2):63 | DOI: 10.36290/der.2021.012  

Delaying surgical procedure in patients with venous leg ulcer leads to treatment prolongation

MUDr. Júlia Černohorská, Ph.D.

Dermatol. praxi. 2021;15(2):67-73 | DOI: 10.36290/der.2021.013  

Chronic venous disease (CVD) of the lower limbs is currently among the most widespread lifestyle diseases, and the impact on the quality of life of patients with this disease is similar to that of living with hypertension, diabetes, or asthma. Statistics indicate that one in two women and one in four men suffer from CVD. However, the vast majority of people do not address this problem. For this reason, the disease progresses to the form of a leg ulcer which is the terminal stage of chronic venous insufficiency. According to recent estimates, 0.3-1.0% of adult population over 65 years of age will develop a leg ulcer. Venous leg ulcer is typically accompanied...

Myths and pitfalls in management of patient with infantile hemangioma

MUDr. Josef Mališ, MUDr. Adéla Mišove

Dermatol. praxi. 2021;15(2):74-76  

Infantile hemangioma occurs in 5 to 10 % of children under one year of age. This benign vascular tumor is characterized by three phases of growth - proliferation, plateau, involution. Superficial hemangiomas reach their maximum size in 6 to 8 months, in deep ones rarely up to 2 years. Modern non-selective β-blocker therapy - propranolol - offers children an effective, safe and non-invasive solution. Starting the therapy in the proliferative phase is crucial for effectiveness.

Current options of non-surgical treatment of melanoma in practice

MUDr. Miroslav Důra

Dermatol. praxi. 2021;15(2):78-82 | DOI: 10.36290/der.2021.015  

Melanoma is the most malignant skin cancer known for its high mortality rate and delayed formation of metastases. The treatment of metastatic melanoma is currently going through a golden age since novel drugs from the classes of immunotherapeutics and targeted agents are becoming available on the market. These drugs significantly increase the rate of induced remissions and prolong overall survival. The mechanism of action of immunotherapeutic drugs is based on blocking of inhibitory immune checkpoints in order to increase the efficacy of the body's own immune system against tumour cells. As more modern agents are being introduced into the market, a...

How to prevent acne fulminans sine fulminans

MUDr. Zuzana Nevoralová, Ph.D.

Dermatol. praxi. 2021;15(2):83-88 | DOI: 10.36290/der.2021.016  

A case report of a 16-year-old boy with a severe form of acne and with asthma is described. Because of severe state of the patient a treatment with peroral isotretinoin was choosen. To prevent isotretinoin-induced acne fulminans an addition of peroral steroids during the first months of the treatment was necessary. Through the initial very severy condition a complete healing was reached, only small inequalities and scars remained. Asthma was compensated during the whole therapy. Subsequently, the patient applies topical adapalene to prevent acne recurrence.

Risankizumab in the treatment of erythrodermic form of psoriasis in patient with associated sclerodermia

MUDr. Jan Šternberský, Ph.D., MUDr. Martin Tichý, Ph.D.

Dermatol. praxi. 2021;15(2):89-93 | DOI: 10.36290/der.2021.017  

Risankizumab is one of the newest biologic drugs used for the treatment of severe forms of psoriasis. It is humanized antibody aimed against p19 subunit of interleukin 23, which is the key initiating cytokin in the pathogenesis of psoriasis. Risankizumab has got excellent therapeutic response with longterm effect not only in clinical trials, but also in the real clinical practice. Up to date safety data are also very favorable. The case report describes excellent effect of risankizumab in the treatment of erythrodermic form of psoriasis in patient with associated sclerodermia.

Biological treatment of severe atopic dermatitis in an adolescent patient

MUDr. Radana Zachová

Dermatol. praxi. 2021;15(2):94-96 | DOI: 10.36290/der.2021.018  

We are presenting a case report of a boy with severe atopic dermatitis refractory to systemic immunosupresive treatment with growth retardation, secondary hypocorticalism after repeated systemic corticotherapy. Treatment with monoclonal antibody inhibiting alpha subunit of interleukin 4 receptor (IL-4Rα) dupilumab was successfull.

Bullous pemphigoid unwanted effect new oral diabetes drugs

MUDr. et Bc. Petra Pochmanová

Dermatol. praxi. 2021;15(2):98-101 | DOI: 10.36290/der.2021.019  

Association between the development of bullous pemphigoid and the use of some medicinal products, such as diuretics (spironolactone, furosemide) or some neuroleptics, is well documented in the literature. New oral diabetes drugs of glyptin type or inhibitors of dipeptidylpeptidase have expended this spectrum in recent years. Since 2018, 4 patiens with bullous dermatosis have been hospitalized in our dermatology department while taking linagliptin. This article aims to draw the attention of medical community to a possible increased incidence of bullous pemphigoid among diabetics patients who are treated with gliptins.

Nové možnosti prevence a doplňkové léčby aktinické keratózy a nemelanomových kožních nádorů

MUDr. Andrea Kozárová, PhD.

Dermatol. praxi. 2021;15(2):112-114  

Photoprotection in kids

doc. MUDr. Karel Ettler, CSc.

Dermatol. praxi. 2021;15(2):108-110  

Photoprotection is the protection against exposure of the skin to the side effects of sunlight. This includes, in particular, staying in the shade, wearing photoprotective clothing, applying sunscreens and eye protection. Children's skin is more sensitive to sunlight than adults. The growing incidence of skin tumors necessitates continuous lifelong photoprotection from childhood.

Rituximab

prof. MUDr. Hana Jedličková, Ph.D.

Dermatol. praxi. 2021;15(2):105-107 | DOI: 10.36290/der.2021.021  

Rituximab is a monoclonal antibody to the CD20 antigen of B lymphocytes, primarily used in the therapy of haemato-oncologic diseases. Its effect is depletion of B lymphocytes and so it is also used in the therapy of autoimmune diseases, including bullous dermatoses, especially pemphigus. Its early administration in pemphigus has been shown to significantly shorten the time to remission and reduce the total dose of corticosteroids and immunosuppressants administered.

Cutaneous superficial angiomyxoma with a basaloid/follicular hyperplasia of the epidermis

MUDr. PhDr. Vladimír Bartoš, PhD., MPH

Dermatol. praxi. 2021;15(2):102-104  

Superficial angiomyxoma is a benign skin tumor composed of a myxoid matrix and numerous thin-walled blood vessels. It may occur in sporadic form or as a part of Carney complex that is characterized by multiple cutaneous and cardiac myxomas, pigmented lesions of skin and mucosa, and endocrinologic abnormalities. Superficial angiomyxoma is sometimes accompanied by changes of overlying epidermis that may mimic another type of tumor and cause a diagnostic dilemma. The author describes a 26-year-old man with a superficial angiomyxoma arising on the chest that has been histologically accompanied by basaloid/follicular epidermal hyperplasia (BFEH). It was...